Clinical trials
Metabolic Syndrome trials in Sweden
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Unknown status | 3 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lund University | 13 |
| Göteborg University | 4 |
| Vastra Gotaland Region | 4 |
| Karolinska Institutet | 2 |
| Chalmers University of Technology | 1 |
| DoubleGood AB | 1 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1 |
| Linkoeping University | 1 |
| Linnaeus University | 1 |
| Marjukka Kolehmainen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Metabolic Syndrome | 36 |
| Obesity | 10 |
| Inflammation | 6 |
| Diabetes Mellitus, Type 2 | 5 |
| Insulin Resistance | 5 |
| Overweight | 4 |
| Cardiovascular Diseases | 3 |
| Hypertension | 3 |
| Obesity, Abdominal | 3 |
| Diabetes Mellitus | 2 |
Trials
Showing 1 to 25 of 36. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.